Fc region variant

Patent metadata

Field	Value
Publication number	US-11267868-B2
Application number	US-201414781069-A
Country	US
Kind code	B2
Filing date	Apr 2, 2014
Priority date	Apr 2, 2013
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating FcγRs, in particular FcγRIIa (R type), while maintaining its FcγRIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.

First claim

The invention claimed is:

1. An Fc region variant comprising a human IgG Fc region comprising Gln at position 237 (EU numbering), Asp at position 238 (EU numbering), and one of the following combinations (i) to (x) (all positions by EU numbering):
(i) Met at position 241, Glu at position 296, His at position 330, and His at position 324; or
(ii) Met at position 241, Pro at position 268, Glu at position 296, and His at position 330; or
(iii) Phe at position 235, Met at position 241, Glu at position 296, and His at position 324; or
(iv) Phe at position 235, Met at position 241, Pro at position 268, and Glu at position 296; or
(v) Met at position 241, Pro at position 268, Glu at position 296, and His at position 324; or
(vi) Phe at position 235, Met at position 241, Pro at position 268, Glu at position 296, and His at position 324; or
(vii) Phe at position 235, Met at position 241, Glu at position 296, His at position 330, and His at position 324; or
(viii) Phe at position 235, Met at position 241, Pro at position 268, Glu at position 296, and His at position 330; or
(ix) Met at position 241, Pro at position 268, Glu at position 296, His at position 330, and His position 324; or
(x) Asp at position 233, Ile at position 264, Arg at position 267, Pro at position 268, Gly at position 271, and Glu at position 296.

2. An Fc region variant comprising a human IgG Fc region comprising Gln at position 237 (EU numbering), Asp at position 238 (EU numbering), and one of the following combinations (i) to (iv) (all positions by EU numbering):
(i) Met at position 241 and Glu at position 296; or
(ii) Met at position 241, Glu at position 296, and His at position 330; or
(iii) Phe at position 235, Met at position 241, and Glu at position 296; or
(iv) Phe at position 235, Met at position 241, Glu at position 296, and His at position 330.

3. An Fc region variant comprising a human IgG Fc region comprising one of the following combinations (i) to (x) (all positions by EU numbering):
(i) Gln at position 237, Asp at position 238, Met at position 241, Glu at position 296, His at position 324, and His at position 330; or
(ii) Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296, and His at position 330; or
(iii) Phe at position 235, Gln at position 237, Asp at position 238, Met at position 241, Glu at position 296, and His at position 324; or
(iv) Phe at position 235, Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296; or
(v) Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296, and His at position 324; or
(vi) Phe at position 235, Asp at position 238, Pro at position 268, Glu at position 296, and His at position 324; or
(vii) Phe at position 235, Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296, and His at position 324; or
(viii) Phe at position 235, Gln at position 237, Asp at position 238, Met at position 241, Glu at position 296, His at position 324, and His at position 330; or
(ix) Phe at position 235, Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296, and His at position 330; or
(x) Gln at position 237, Asp at position 238, Met at position 241, Pro at position 268, Glu at position 296, His at position 324, and His at position 330.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Mimoto Futa
• Katada Hitoshi
• Igawa Tomoyuki

Classifications

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P11/02

  Nasal agents, e.g. decongestants · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title